

Collateral Thinking

The risk of contagion

Top of the stack

The spread of COVID-19 has added to existing macroeconomic headwinds, and downside risks have increased. Leveraged credit ETFs have seen record redemptions, our economics team has cut the global growth forecast to the lowest since 2009, and the rates market is pricing in three rate cuts. We think the macroeconomic backdrop is likely to get worse before it gets better. As such we think loan spreads could widen out to 600bps in the near term. Headwinds for the loan market come from the potential of a) muted corporate earnings b) retail outflows c) possible contagion from other asset classes.

We think it's prudent to lighten up on riskier paper with the intention of pivoting towards select BB and high single-B names that fall to attractive valuations in sympathy. The proportion of loans trading par and above has swiftly dropped from 60% in January to 35% today, with more than half that distance covered just in the last 3 days. We think this trajectory is likely to continue, likely creating opportunities to buy over the next few weeks. However, we prefer layering into higher quality paper first as B3 and below paper could fall before becoming attractive again.

Our 500bps spread target remains intact because of our expectation that the economic impact of the disease will be transitory, leading to a meaningful rebound once we are over the hump. Given the fluid nature of the situation, we remain in a wait and watch mode, and may revisit our numbers should economic disruption and the ensuing earnings decline appear to be longer lasting or difficult to reverse.

Market technicals

Over the last four weeks, cumulative demand for loans has totaled \$10.4bn (vs \$6.2bn for the previous four-week period), signaling a small pickup in the market. New issuance has totaled \$52.3bn last four weeks. On the YTD basis, supply has outweighed demand by \$36.5bn as of Feb 21st. Retail funds have swung to outflows after temporary inflows earlier this year, as investors have become more cautious.

Performance

Loans in the LCD index returns were flat during the last four weeks. Lower quality has outperformed within rating categories, highlighted by a 29bp gain within CCCs during the week ending in Feb 14th, though they have come under pressure since then. The most liquid loans as per the LCD Leveraged Loan 100 benchmark have returned a cumulative -21bps during the last four weeks, underperforming the broader All Loans index.

Primary market activity

Impacted by the increased uncertainty and volatility in the global market, primary market activity slowed down in the past few weeks. MTD issuance is at \$39.4bn, posting a 40% decrease compared to January issuance of \$64.7bn. YTD, half of the total new money was raised for refinancing (\$51.0bn), while issuances for acquisition-related financing (27%) and LBO (19%) also increased.

This document is intended for BofA Securities institutional investors only. It may not be distributed to financial advisors, retail clients or retail prospects. BofA Securities does and seeks to do business with issuers covered in its research reports. As a result, investors should be aware that the firm may have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only a single factor in making their investment decision. Refer to important disclosures on page 13 to 15.

12099283

Timestamp: 28 February 2020 07:20AM EST

28 February 2020

Leveraged Loan Strategy
United StatesBofA
Data
Analytics

Neha Khoda
Credit Strategist
BofAS
+1 646 855 9656
neha.khoda@bofa.com

Angelina Xu
Credit Strategist
BofAS
+1 646 855 6274
angelina.xu@bofa.com

Table 1: Loan performance

Index	Level	1wk Δ	2wk Δ	YTD Rtn
All Loan	96.3 pts	-0.4	-0.4	+0.3%
BBs	99.0 pts	-0.4	-0.4	-0.0%
Bs	97.4 pts	-0.4	-0.4	+0.5%
CCCs	82.6 pts	-1.1	-0.8	+0.7%

Source: S&P LCD

Table 2: HY performance

Index	Level	1wk Δ	2wk Δ	YTD Rtn
US HY	427 bps	+70	+68	+0.0%
BBs	265 bps	+61	+60	+0.3%
Bs	434 bps	+82	+76	-0.1%
CCCs	1066 bps	+82	+85	-0.4%

Source: BofA Global Research

Table 3: Fund flows (\$mn)


Asset	1wk	2wk	YTD	LTM
Loans	-230	-118	-30,616	-35,446
US HY	-155	+2,239	+11,203	+17,692
US IG	+6,953	+7,808	+186,886	+327,965

Source: EPFR Global

Top of the stack

The loan market has been hovering in +/- 20bps range of our 500bps target for the last 11 weeks. Now with COVID-19 adding to a range of existing macroeconomic headwinds, downside risks have noticeably increased. There have been major redemptions in the leveraged ETF space with both HYG and SRLN posting record one-day outflows this past week, our economics team has downgraded their global growth forecast to 2.8%, the lowest since 2009 (Chart 1), and the rates market is already pricing in 3 rate cuts (Chart 2).

Chart 1: Fading GDP growth, % yoy



Source: BofA Global Research, BEA, UK Office of National Statistics, Cabinet Office of Japan, Statistical Office of the European Communities

Chart 2: Markets pricing in 3 rate cuts over next 12 months



Source: Bloomberg

We think the macroeconomic backdrop is likely to deteriorate further before bouncing back. As such we think that loan spreads may widen out to as much as 600bps from here, before stabilizing in the back half of the year. We are not changing our spread target because of our expectation that the economic impact of the disease will be transitory, which could lead to a meaningful rebound once we are over the hump. Given the fluid nature of the situation, we remain in a wait and watch mode, and may revisit our numbers should economic disruption and the ensuing earnings decline appear to be longer lasting or difficult to reverse.

The whack-a-mole economy

Our economy cannot catch a break. We spent a better part of this business cycle in a soft patch, and finally when green shoots began to emerge globally late last year, we have been dealt with a series of economic blows. First, [it turns out](#) that the damage to business confidence from years of trade war uncertainty was deeper than realized. Further, Boeing's halt in production of its 737 Max model has negatively impacted global supply chains and is depressing equity market earnings; US-Iran tensions are still simmering; and political volatility is likely to remain elevated in an election year. Now, in the wake of the rapidly evolving Coronavirus situation, we have a new concern. Though China spread seems to be plateauing, transmissions in South Korea and Europe are on the rise. The discovery of clusters of community spread (without an epidemiological link and hence untraceable) in new countries, has made the situation more concerning.

For those expecting an instant snap back after the health crisis passes, China serves as a good example, in our view. Although the Chinese government has been encouraging the resumption of normal activities, the recovery since the extended Lunar New Year holiday has been very slow, and it may be a few months before normalcy returns. Given that many countries around the world, including the US, are seemingly at the very beginning of the COVID-19 wave, it could logically keep financial markets anxious. In a nutshell, we think things are likely to get worse before they get better.

The keyword here is *better*. Our base case still remains that the global economy will recover from the Coronavirus jolt, albeit our Economists now believe that it will play out in a ["U-shape"](#) rather than a "V-shape". The underlying US economy remains on a strong




footing and has the capacity to withstand a few hiccups. In January, core CPI grew 2.5% YoY, the economy added 225k jobs, average hourly earnings rose by 3.1% yoy and labor force participation rate improved to 63.4%, suggesting a strong consumer and labor force. Our Econ team's [big-data analysis](#) of the US business cycle suggests that the aggregate performance of the US economy has been akin to the country being in a "Boom" since November 2019, though that is likely to dampen going forward. Note that while the pace of recovery may have changed, the direction has not. The big question is whether or not the economic damage inflicted through the duration of the virus outbreak will be reversible. For now the answer is a Yes, but we'll know more over the next few weeks.

Loan valuations


Influenced by the changing macro backdrop, loan spreads which had been grinding tighter since Dec, have taken a breather this month. Current loan 2yr DM is 520bps, ~30bps off the tightness reached a month ago. In terms of ratings, while January saw investors reaching down the credit spectrum for yield, riskier loans are lagging as investors are becoming more cautious (Chart 3). The monthly return profiles below show that divide.

Chart 3: MTD February return profile




Source: BofA Global Research, S&P LCD, ICE Indices

Chart 4: January return profile




Source: BofA Global Research, S&P LCD, ICE Indices

In terms of relative value, since loans did not rally to the extent that HY and IG did over the last 12 months (Chart 4), they have lesser to lose to begin with. While loans have widened 8% (40bps) since their Jan tightness, the retracement in HY and IG has been comparatively starker. Currently at 115bps, IG has widened more than 10% from the 2019 year end tightness (101bps in December) and HY has retraced over 15% (360bps in December, 427bps currently).

Chart 4: Loans did not rally as much as HY and IG in 2019

Source: BofA Global Research, S&P LCD, Bloomberg

Chart 5: Loan-bond relative value has collapsed to 34bps

Source: BofA Global Research, S&P LCD

Given the large move in HY spreads, the large dislocation that our relative value model pointed to at the end of last year has now been corrected. Chart 5 shows the difference between the actual and fair-value loan spreads estimated based on their long-term relationship with HY spreads (error term). The higher the error term, the more undervalued loans are vs HY bonds. This metric has decreased from 150bps in December 2019 to 34bps currently, indicating that the dislocation has rapidly closed, bringing both asset classes more in line. Looking at yields, HY bond yields have ticked up slightly while loan YTM has edged down, bringing the two yields to ~6%, [correcting](#) another anomaly that had been existing since June 2019, only the 2nd time in history that this has happened.

Chart 6: Loan yields similar to HY now

Source: BofA Global Research, S&P LCD, ICE Indices

On an absolute basis, we think loan spreads will remain under pressure in the near term, especially in the B3 and CCC space. While our long-term spread target remains at 500bps, we think loan spreads could widen out to touch 600bps in the interim. Headwinds for the loan market come in the form of a) potentially muted corporate earnings growth in Q1 and Q2, b) retail outflows, c) contagion from other asset classes.

We have addressed the first risk earlier on. On the subject of technicals, ETFs have reacted fiercely, and given enough time, potentially they could lead to outflows from open end funds as well. Expectations of rate cuts have already reached -75bps, and chances are that a portion of that will be met once the true extent of economic impact becomes apparent to the official sector. This will further dampen demand from the yield-sensitive retail community. Granted that retail plays a much smaller role in the loan market today, but there aren't many replacement options given that Japanese money is



still sitting out of the market. Finally, there is also a significant spillover risk from other asset classes such as equities and HY that have a higher beta to loans, and have registered larger corrections from their peaks.

What we think here

Going forward, we remain in a wait and watch mode. The Coronavirus situation is a wild card. Its contagiousness combined with the ability to spread in a stealth mode (without patients being symptomatic) poses a serious threat of disrupting everyday lives in the US, should the government take extreme measures in a proactive or reactive manner. At the same time there is a chance that as more becomes known about the virus (mortality rate, incubation period, medical intervention), concerns alleviate and the ultimate impact softens. We think it will take some time for the markets to assess the true economic fallout from the virus. Until then it remains prudent to remain cautious and nimble.

We think it makes sense to lighten up on riskier paper and accumulate cash, with the intention of pivoting towards select BB and high single-B names that fall to attractive valuations in sympathy, as we navigate the coronavirus. The proportion of loans trading above par has already dropped from 60% in January to 35% today, with more than half that distance covered just in the last 3 days. We think this trajectory is likely to continue, creating opportunities to buy in over the next few weeks. However, we prefer layering into higher quality paper first as B3 below paper has ways to fall before it looks attractive again.

Chart 7: Proportion of loans trading at or above par




Source: BofA Global Research, S&P LCD, LPC

The softer market, in our view, dampens our repricings expectations in 1H20. However, as long as the fallout remains transitory, and the economy bounces back from the COVID-19 epidemic, the underpinning of a future repricings wave remains intact, albeit the timing might shift to the 2nd half of this year. All told, our concerns don't reflect the end of a cycle. We believe that this blip will just temporarily redirect demand towards safer yields, and as the situation improves, the reach will once again percolate down the credit spectrum. As such, for the time being, we consider any major selloffs as opportunities to buy into solid credits in the belly of the ratings curve.

Q4 earnings Update

Now that 55% of loan issuers we track have reported Q4 earnings, we take a peek at how earnings are turning out. Both EPS and revenue beats were better than 3Q, as 64% reported EPS beats (vs 56% in 3Q) and 63% reported revenue beats (vs 50% in 3Q). The elevated business confidence and increased end demand from the "Phase-1" deal between China and the US helped improve the fundamentals. Lower rating category issuers outperformed higher rating categories (Chart 8). Among the issuers that reported earnings in Q4, 67% of B3 & below issuers reported both EPS and revenue beat, compared to 48% of B1 & B2 issuers and 46% of BB issuers.

Chart 8: Q4 2019 loan issuer beats by rating category

Source: BofA Global Research, Bloomberg

Sector-wise, manufacturing-related sectors (Capital Goods, Transportation) and commodity-related sectors (Utilities, Materials) generated the highest EPS beats (Table 4). Retail topped all other sectors in terms of revenue beats, likely attributable to the holiday season sales boost. Financials, Healthcare and Technology the three biggest loan sectors, are currently in the better half of the leader board in terms of both EPS and Revenue beats.

Table 4: Q4 2019 loan issuer beats by sector

	Face Outstanding	All reporting issuers	Issuers reported	% reported	EPS Beat	Rev Beat	Both Beat
Utilities	23,319	4	1	25%	100%	100%	100%
Financials	125,306	18	12	67%	100%	75%	75%
Capital Goods	51,854	18	12	67%	83%	75%	67%
Retail	85,866	21	5	24%	60%	80%	60%
Healthcare	145,090	27	12	44%	75%	75%	58%
Technology	173,948	28	21	75%	62%	76%	52%
Telecoms	47,441	13	8	62%	63%	75%	50%
Services	110,870	29	13	45%	54%	69%	46%
Autos	37,213	18	11	61%	64%	55%	45%
Real Estate	53,258	15	7	47%	57%	71%	43%
Chemicals	50,504	14	8	57%	75%	38%	38%
Cable/Media	96,142	28	8	29%	38%	63%	38%
Transportation	32,271	4	3	75%	67%	67%	33%
Gaming	34,827	11	3	27%	33%	33%	33%
Energy	58,087	14	7	50%	43%	43%	29%
Materials	42,545	8	3	38%	67%	33%	0%
Food Producers	37,776	8	2	25%	100%	0%	0%
All	1,206,317	278	136	49%	66%	65%	49%

Source: BofA Global Research, Bloomberg

Market Technicals

Over the last four weeks, cumulative demand for loans has totaled \$10.4bn (vs \$6.2bn for the previous four-week period), signaling a small pickup in the market. New issuance has totaled \$52.3bn last four weeks. CLO formation remained soft with CLO arbitrage ticking downwards since November 2019. On the supply side, last four weeks saw heavy new issuances of \$15.9bn, \$16.3bn, and \$27.1bn for the weeks ending in Feb 7th, Jan 31st, and Jan 24th respectively. On the YTD basis, supply has outweighed demand by \$36.5bn as of Feb 21st. Retail funds saw the comeback of outflows after temporary inflows earlier this year, as investors have become more cautious facing the uncertain macro backdrop.

Table 5: Weekly Technicals (\$mns)

	YTD as of				
	2/21/20	2/14/20	2/7/20	1/31/20	1/24/20
Retail flows (a)	-536	-103	-292	-380	-235
CLO creation (b)	6,135	733	3,354	1,673	406



Table 5: Weekly Technicals (\$mns)

	YTD as of 2/21/20	2/14/20	2/7/20	1/31/20	1/24/20
Coupons (c)	8,328	976	1,893	1,520	843
Demand (a+b+c)	13,927	1,606	4,955	2,813	1,014
Issuance Ex -repricings (d)	80,701	4,245	15,971	16,430	27,051
Repayments (e)	30,261	NA	14,650	4,510	1,653
Supply (d-e)	50,439	NA	1,321	11,920	25,398
Demand net of Supply	-36,512	NA	3,634	-9,107	-24,384

Source: S&P LCD, EPFR Global.

Values in \$mn. Weekly coupon values are estimated by dividing each month's coupon payment by 4.

Performance by segment

Loans in the LCD index returns were flat during the last four weeks. 2nd liens outperformed MTD with weekly returns of 18bps, 23bps, and 31bps for the weeks ending in Feb 21st, Feb 14th and Feb 7th respectively. Within ratings, lower quality has outperformed, highlighted by a 29bp gain within CCCs during the week ending in Feb 14th, though they have come under pressure since then. The most liquid loans as per the LCD Leveraged Loan 100 benchmark have returned a cumulative -21bps during the last four weeks, underperforming the broader All Loans index.

Table 6: Total Returns (price plus coupon return), bps

	2/21/2020	2/14/2020	2/7/2020	1/31/2020
All Loans	11	12	-5	-23
BB	3	7	-8	-17
B	14	13	-2	-26
CCC	9	29	-16	-37
2nd Lien	18	23	31	-9
LL100	9	16	-15	-31
Middle Market	16	10	13	2

Source: S&P LCD

Middle market defined as \$50mn EBITDA or less. LL100 composed of the 100 largest issuers (by face value) in the S&P LCD Leveraged Loan Index.

Primary market activity

Impacted by the increased uncertainty and volatility in the global market, primary market activity slowed down in the past few weeks. MTD issuance is at \$39.4bn, posting a 40% decrease compared to January issuance of \$64.7bn. YTD, half of the total new money was raised for refinancing (\$51.0bn), while issuances for acquisition-related financing (27%) and LBO (19%) also increased. Technology (\$18.2bn) and Healthcare (\$17.0bn) continued to dominate the primary market YTD, as a combined 38% of total new issuance amount was in these two sectors. The largest deal last week came from Bausch Health in a \$5.1bn refinancing offering.

Table 7: Recent loan new issues


Launch Dt	Issuer	Deal Name	Size	New Inst. Money	Moody's	S&P	ABL	Cov	Lite	Proceeds	Sector	Country
2/26/2020	Atlas Technical Consultants	Atlas Technical (3/20)	281	281	NR	NR	No	Yes		Acquisition	Building Materials	United States
2/25/2020	Boels	Boels (3/20)	1,810	1610	B1	BB-		NO		Acquisition-related	Services & Leasing	Netherlands
2/25/2020	Capstone Logistics	Capstone Logistics (TL 3/20)	395	395	B3	B-	No	No		Refinancing	Services & Leasing	United States
2/25/2020	Cook & Boardman	Cook & Boardman (Add-on 3/20)	75	75	B3	B	No	No		Acquisition	Building Materials	United States
2/25/2020	Duff & Phelps LLC	Duff & Phelps (TL 3/20)	1,550	1550	B2	B	No	Yes		LBO	Services & Leasing	United States
2/25/2020	Duravant LLC	Duravant (Add-on TL 3/20)	155	155	B2	B-	No	Yes		Acquisition	Manufacturing & Machinery	United States
2/25/2020	Gerflor Group	Gerflor (RC 3/20)	125	125	B2	B		NO		Acquisition-related	Home Furnishings	France
2/25/2020	Gerflor Group	Gerflor (TL 3/20)	850	850	B2	B		YES		Acquisition-related	Home Furnishings	France
2/25/2020	Service Logic	Service Logic (Add-on 3/20)	140	140	NR	NR	No	No		Acquisition	Manufacturing & Machinery	United States
2/24/2020	Alkermes Inc	Alkermes (3/20)	350	350	Ba3	BB	No	Yes		Refinancing	Healthcare	Ireland



Table 7: Recent loan new issues

Launch Dt	Issuer	Deal Name	Size	New Inst. Money	Moody's	S&P	ABL	Cov	Lite	Proceeds	Sector	Country
2/21/2020	Allen Media LLC	Allen Media (Add-on 3/20)	25	25	Ba3	BB-	No	Yes		GCP	TV	United States
2/20/2020	Bausch Health	Bausch Health (3/20)	5,144	5144	Ba2	BB	No	Yes		Refinancing	Healthcare	Canada
2/20/2020	C.J. Foods	C.J. Foods (TL 3/20)	285	285	B2	B-	No	Yes		Acquisition	Food & Beverage	United States
2/20/2020	Homblower Yachts Inc	Homblower (Add-on 3/20)	25	25	B2	B	No	Yes		Refinancing	Entertainment & Leisure	United States
2/20/2020	Micro Focus	Micro Focus (EURO TL 3/20)	660	660	B1	BB-		YES		Refinancing	Computers & Electronics	United Kingdom
2/20/2020	Micro Focus	Micro Focus (US TL 3/20)	718	718	B1	BB-	No	Yes		Refinancing	Computers & Electronics	United Kingdom
2/20/2020	SnapAV	SnapAV (Add-on 2nd Lien 3/20)	100	100	NR	B	No	No		Acquisition	Computers & Electronics	United States
2/20/2020	SnapAV	SnapAV (Add-on TL 3/20)	290	290	B2	B	No	Yes		Acquisition	Computers & Electronics	United States
2/20/2020	Tosca Services	Tosca Services (3/20)	325	325	B2	B	No	Yes		Acquisition	Chemicals	United States
2/20/2020	Vistage Worldwide	Vistage (Add-on 3/20)	50	50	B2	B	No	Yes		Refinancing	Services & Leasing	United States


Source: S&P LCD

Chart 9: Average new issue yields by month

Source: S&P LCD

Instinct® Loans

To track market sentiment, we look at data from BofA's electronic loan trading platform, *Instinct®*, which clients use to trade some of the most liquid loans in the market. Demand trailed down as the uncertainties in the global economy remain strong and the recent Coronavirus deterioration in Japan and Korea put Asia under pressure. The daily mid changes barely stayed positive during this period and the running mid change fell down to the negative territory.

Chart 10: Instinct® Loans Market Monitor

Source: BofA Instinct® Loans


Left y-axis shows bid/offer interest; right y-axis shows average mid-price change.



Appendix

CLOs are an important factor to consider in the loan market given they are the single biggest buyer of loans and represent 70% of the primary demand within this asset class. Loan retail funds are the second largest buyers although their participation has shrunk since the peaks of 2013. Since then, we have seen increasing activity from CLO managers. At the same time, hedge, distressed & high yield funds have played a lesser role in the primary market.


Chart 11: Primary institutional investor market by type



Source: S&P LCD


Three generations of CLOs exist today, CLO 1.0 (pre-crisis), and CLO 2.0/CLO 3.0 (post-crisis). The market is primarily driven by the latter. Below charts show CLO spread levels by tranches.

Chart 12: US CLO 1.0 indicative spread levels (bps)




Source: Intex

Chart 13: US CLO 2.0/3.0 indicative spread levels (bps)



Source: Intex

CLO arbitrage is a widely followed statistic in the loan market, and represents the theoretical spread that managers can capture by issuing CLOs. The below chart compares CLO asset (loan) spreads to the weighted average spreads of CLO liabilities. The difference between these two values is the theoretical arbitrage and represents the current attractiveness of creating new CLOs. A higher arbitrage number means a greater incentive for managers to bring new CLOs to the market, and thus provide incremental loan demand, and vice versa.


Chart 14: CLO arbitrage (bps)

Source: S&P LCD

Arbitrage: Loan asset spread - WA CLO spread X liability %.

Loan spreads (running avg 8wks) 60% new-issue: B+/B, 20% sec B 20% sec BB.


Chart below shows monthly CLO returns as defined by the Palmer Square CLO index (price plus coupon returns).

Chart 15: Monthly CLO 2.0 returns by rating


Source: PriceServe, Palmer Square CLO Indices, Bloomberg

Since technicals play a big role in the loan market, following retail patterns is also essential. In general, we see that the performance of the BB section of the loan market correlates most with retail flows, while new CLO issuance seems to correlate to B Loan returns. This makes sense as mutual funds generally gravitate towards less risky investments while CLOs invest in single B rated assets on average. Chart 16 shows a measure of retail flows (12 week trailing retail flows as a percentage of outstanding AUM) vs. monthly BB Loan total returns, while Chart 17 depicts monthly CLO issuance vs. monthly B Loan total returns.



Chart 16: BB performance vs Loan retail flows

Source: S&P LCD, EPFR Global

Chart 17: B performance vs CLO creation

Source: S&P LCD, EPFR Global



Disclosures

Important Disclosures

BofA Global Research Credit Opinion Key

BofA Global Research provides recommendations on an issuer's bonds (including corporate and sovereign external debt securities), loans, capital securities, equity preferreds and CDS as described below. Convertible securities are not rated. An issuer level recommendation may also be provided for an issuer as explained below. BofA Global Research credit recommendations are assigned using a three-month time horizon.

Issuer Recommendations: If an issuer credit recommendation is provided, it is applicable to bonds and capital securities of the issuer except bonds and capital securities specifically referenced in the report with a different credit recommendation. Where there is no issuer credit recommendation, only individual bonds and capital securities with specific recommendations are covered. Loans, CDS and equity preferreds are rated separately and issuer recommendations do not apply to them.

BofA Global Research credit recommendations are assigned using a three-month time horizon:

Overweight: Spreads and /or excess returns are likely to outperform the relevant and comparable market over the next three months.

Marketweight: Spreads and/or excess returns are likely to perform in-line with the relevant and comparable market over the next three months.

Underweight: Spreads and/or excess returns are likely to underperform the relevant and comparable market over the next three months.

BofA Global Research uses the following rating system with respect to **Credit Default Swaps (CDS):**

Buy Protection: Buy CDS, therefore going short credit risk

Neutral: No purchase or sale of CDS is recommended.

Sell Protection: Sell CDS, therefore going long credit risk

Due to the nature of strategic analysis, the issuers or securities recommended or discussed in this report are not continuously followed. Accordingly, investors must regard this report as providing stand-alone analysis and should not expect continuing analysis or additional reports relating to such issuers and/or securities.

BofA Global Research personnel (including the analyst(s) responsible for this report) receive compensation based upon, among other factors, the overall profitability of Bank of America Corporation, including profits derived from investment banking. The analyst(s) responsible for this report may also receive compensation based upon, among other factors, the overall profitability of the Bank's sales and trading businesses relating to the class of securities or financial instruments for which such analyst is responsible.

BofA Securities fixed income analysts regularly interact with sales and trading desk personnel in connection with their research, including to ascertain pricing and liquidity in the fixed income markets.

Other Important Disclosures

Prices are indicative and for information purposes only. Except as otherwise stated in the report, for the purpose of any recommendation in relation to: (i) an equity security, the price referenced is the publicly traded price of the security as of close of business on the day prior to the date of the report or, if the report is published during intraday trading, the price referenced is indicative of the traded price as of the date and time of the report; or (ii) a debt security (including equity preferred and CDS), prices are indicative as of the date and time of the report and are from various sources including BofA Securities trading desks.

The date and time of completion of the production of any recommendation in this report shall be the date and time of dissemination of this report as recorded in the report timestamp.

This report may refer to fixed income securities or other financial instruments that may not be offered or sold in one or more states or jurisdictions, or to certain categories of investors, including retail investors. Readers of this report are advised that any discussion, recommendation or other mention of such instruments is not a solicitation or offer to transact in such instruments. Investors should contact their BofA Merrill Lynch representative or Merrill Lynch Global Wealth Management financial advisor for information relating to such instruments. Rule 144A securities may be offered or sold only to persons in the U.S. who are Qualified Institutional Buyers within the meaning of Rule 144A under the Securities Act of 1933, as amended. SECURITIES OR OTHER FINANCIAL INSTRUMENTS DISCUSSED HEREIN MAY BE RATED BELOW INVESTMENT GRADE AND SHOULD THEREFORE ONLY BE CONSIDERED FOR INCLUSION IN ACCOUNTS QUALIFIED FOR SPECULATIVE INVESTMENT.

Recipients who are not institutional investors or market professionals should seek the advice of their independent financial advisor before considering information in this report in connection with any investment decision, or for a necessary explanation of its contents.

The securities or other financial instruments discussed in this report may be traded over-the-counter. Retail sales and/or distribution of this report may be made only in states where these instruments are exempt from registration or have been qualified for sale.

Officers of BofAS or one or more of its affiliates (other than research analysts) may have a financial interest in securities of the issuer(s) or in related investments.

This report, and the securities or other financial instruments discussed herein, may not be eligible for distribution or sale in all countries or to certain categories of investors, including retail investors.

Information relating to Affiliates of BofAS, MLPF&S and Distribution of Affiliate Research Reports:

BofA Global Research policies relating to conflicts of interest are described at <https://rsch.baml.com/coj>

"BofA Securities" includes BofA Securities, Inc. ("BofAS") and its affiliates. Investors should contact their BofA Securities representative or Merrill Global Wealth Management financial advisor if they have questions concerning this report or concerning the appropriateness of any investment idea described herein for such investor. "BofA Securities" is a global brand for BofA Global Research.

BofAS and/or Merrill Lynch, Pierce, Fenner & Smith ("MLPF&S") may in the future distribute, information of the following non-US affiliates in the US (short name: legal name, regulator): Merrill Lynch (South Africa): Merrill Lynch South Africa (Pty) Ltd., regulated by The Financial Service Board; MLI (UK): Merrill Lynch International, regulated by the Financial Conduct Authority (FCA) and the Prudential Regulation Authority (PRA); BofASE (France): BofA Securities Europe SA is authorized by the Autorité de Contrôle Prudentiel et de Résolution (ACPR) and regulated by the ACPR and the Autorité des Marchés Financiers (AMF); BAMLI DAC (Milan): Bank of America Merrill Lynch International DAC, Milan Branch, regulated by the Bank of Italy, the European Central Bank (ECB) and the Central Bank of Ireland (CBI); BAMLI DAC (Frankfurt): Bank of America Merrill Lynch International DAC, Frankfurt Branch regulated by BaFin, the ECB and the CBI; Merrill Lynch (Australia): Merrill Lynch Equities (Australia) Limited, regulated by the Australian Securities and Investments Commission; Merrill Lynch (Hong Kong): Merrill Lynch (Asia Pacific) Limited, regulated by the Hong Kong Securities and Futures Commission (HKSF); Merrill Lynch (Singapore): Merrill Lynch (Singapore) Pte Ltd, regulated by the Monetary Authority of Singapore (MAS); Merrill Lynch (Canada): Merrill Lynch Canada Inc, regulated by the Investment Industry Regulatory Organization of Canada; Merrill Lynch (Mexico): Merrill Lynch Mexico, SA de CV, Casa de Bolsa, regulated by the Comisión Nacional Bancaria y de Valores; Merrill Lynch (Argentina): Merrill Lynch Argentina SA, regulated by Comisión Nacional de Valores; Merrill Lynch (Japan): Merrill Lynch Japan Securities Co., Ltd., regulated by the Financial Services Agency; Merrill Lynch (Seoul): Merrill Lynch International, LLC Seoul Branch, regulated by the Financial Supervisory Service; Merrill Lynch (Taiwan): Merrill Lynch Securities (Taiwan) Ltd., regulated by the Securities and Futures Bureau; DSP Merrill Lynch (India): DSP Merrill Lynch Limited, regulated by the Securities and Exchange Board of India; Merrill Lynch (Indonesia): PT Merrill Lynch Sekuritas Indonesia, regulated by Otoritas Jasa Keuangan (OJK); Merrill Lynch (Israel): Merrill Lynch Israel Limited, regulated by Israel Securities Authority; Merrill Lynch (Russia): OOO Merrill Lynch Securities, Moscow, regulated by the Central Bank of the Russian Federation; Merrill Lynch (DIFC): Merrill Lynch International (DIFC Branch), regulated by the Dubai Financial Services Authority (DFSA); Merrill Lynch (Spain): Merrill Lynch Capital Markets Espana, S.A.S.V., regulated by Comisión Nacional del Mercado De Valores; Merrill Lynch (Brazil): Merrill Lynch S.A. Corretora de Títulos e Valores Mobiliários, regulated by Comissão de Valores Mobiliários; Merrill Lynch KSA Company: Merrill Lynch Kingdom of Saudi Arabia Company, regulated by the Capital Market Authority.

This information: has been approved for publication and is distributed in the United Kingdom (UK) to professional clients and eligible counterparties (as each is defined in the rules of the FCA



and the PRA) by MLI (UK), which is authorized by the PRA and regulated by the FCA and the PRA - details about the extent of our regulation by the FCA and PRA are available from us on request; has been approved for publication and is distributed in the European Economic Area (EEA) by BofASE (France), which is authorized by the ACPR and regulated by the ACPR and the AMF; has been considered and distributed in Japan by Merrill Lynch (Japan), a registered securities dealer under the Financial Instruments and Exchange Act in Japan, or its permitted affiliates; is issued and distributed in Hong Kong by Merrill Lynch (Hong Kong) which is regulated by HKSF; is issued and distributed in Taiwan by Merrill Lynch (Taiwan); is issued and distributed in India by DSP Merrill Lynch (India); and is issued and distributed in Singapore to institutional investors and/or accredited investors (each as defined under the Financial Advisers Regulations) by Merrill Lynch (Singapore) (Company Registration No 198602883D). Merrill Lynch (Singapore) is regulated by MAS. Bank of America N.A., Australian Branch (ARBN 064 874 531), AFS License 412901 (BANA Australia) and Merrill Lynch Equities (Australia) Limited (ABN 65 006 276 795), AFS License 235132 (MLEA) distribute this information in Australia only to 'Wholesale' clients as defined by s.761G of the Corporations Act 2001. With the exception of BANA Australia, neither MLEA nor any of its affiliates involved in preparing this information is an Authorised Deposit-Taking Institution under the Banking Act 1959 nor regulated by the Australian Prudential Regulation Authority. No approval is required for publication or distribution of this information in Brazil and its local distribution is by Merrill Lynch (Brazil) in accordance with applicable regulations. Merrill Lynch (DIFC) is authorized and regulated by the DFSA. Information prepared and issued by Merrill Lynch (DIFC) is done so in accordance with the requirements of the DFSA conduct of business rules. BAMLI DAC (Frankfurt) distributes this information in Germany and is regulated by BaFin, the ECB and the CBI. BofA Securities entities, including BAMLI DAC and BofASE (France), may outsource/delegate the marketing and/or provision of certain research services or aspects of research services to other branches or members of the BofA Securities group. You may be contacted by a different BofA Securities entity acting for and on behalf of your service provider where permitted by applicable law. This does not change your service provider. Please use this link <http://www.bankofamerica.com/emaildisclaimer> for further information. This information has been prepared and issued by BofAS and/or one or more of its non-US affiliates. The author(s) of this information may not be licensed to carry on regulated activities in your jurisdiction and, if not licensed, do not hold themselves out as being able to do so. BofAS and/or MLPF&S is the distributor of this information in the US and accepts full responsibility for information distributed to BofAS and/or MLPF&S clients in the US by its non-US affiliates. Any US person receiving this information and wishing to effect any transaction in any security discussed herein should do so through BofAS and/or MLPF&S and not such foreign affiliates. Hong Kong recipients of this information should contact Merrill Lynch (Asia Pacific) Limited in respect of any matters relating to dealing in securities or provision of specific advice on securities or any other matters arising from, or in connection with, this information. Singapore recipients of this information should contact Merrill Lynch (Singapore) Pte Ltd in respect of any matters arising from, or in connection with, this information.

General Investment Related Disclosures:

Taiwan Readers: Neither the information nor any opinion expressed herein constitutes an offer or a solicitation of an offer to transact in any securities or other financial instrument. No part of this report may be used or reproduced or quoted in any manner whatsoever in Taiwan by the press or any other person without the express written consent of BofA Securities. This document provides general information only, and has been prepared for, and is intended for general distribution to, BofA Securities clients. Neither the information nor any opinion expressed constitutes an offer or an invitation to make an offer, to buy or sell any securities or other financial instrument or any derivative related to such securities or instruments (e.g., options, futures, warrants, and contracts for differences). This document is not intended to provide personal investment advice and it does not take into account the specific investment objectives, financial situation and the particular needs of, and is not directed to, any specific person(s). This document and its content do not constitute, and should not be considered to constitute, investment advice for purposes of ERISA, the US tax code, the Investment Advisers Act or otherwise. Investors should seek financial advice regarding the appropriateness of investing in financial instruments and implementing investment strategies discussed or recommended in this document and should understand that statements regarding future prospects may not be realized. Any decision to purchase or subscribe for securities in any offering must be based solely on existing public information on such security or the information in the prospectus or other offering document issued in connection with such offering, and not on this document.

Securities and other financial instruments referred to herein, or recommended, offered or sold by BofA Securities, are not insured by the Federal Deposit Insurance Corporation and are not deposits or other obligations of any insured depository institution (including, Bank of America, N.A.). Investments in general and, derivatives, in particular, involve numerous risks, including, among others, market risk, counterparty default risk and liquidity risk. No security, financial instrument or derivative is suitable for all investors. In some cases, securities and other financial instruments may be difficult to value or sell and reliable information about the value or risks related to the security or financial instrument may be difficult to obtain. Investors should note that income from such securities and other financial instruments, if any, may fluctuate and that price or value of such securities and instruments may rise or fall and, in some cases, investors may lose their entire principal investment. Past performance is not necessarily a guide to future performance. Levels and basis for taxation may change.

BofA Securities is aware that the implementation of the ideas expressed in this report may depend upon an investor's ability to "short" securities or other financial instruments and that such action may be limited by regulations prohibiting or restricting "shortselling" in many jurisdictions. Investors are urged to seek advice regarding the applicability of such regulations prior to executing any short idea contained in this report.

This report may contain a trading idea or recommendation which highlights a specific identified near-term catalyst or event impacting a security, issuer, industry sector or the market generally that presents a transaction opportunity, but does not have any impact on the analyst's particular "Overweight" or "Underweight" rating (which is based on a three month trade horizon). Trading ideas and recommendations may differ directionally from the analyst's rating on a security or issuer because they reflect the impact of a near-term catalyst or event.

Foreign currency rates of exchange may adversely affect the value, price or income of any security or financial instrument mentioned in this report. Investors in such securities and instruments effectively assume currency risk.

UK Readers: The protections provided by the U.K. regulatory regime, including the Financial Services Scheme, do not apply in general to business coordinated by BofA Securities entities located outside of the United Kingdom.

BofAS or one of its affiliates is a regular issuer of traded financial instruments linked to securities that may have been recommended in this report. BofAS or one of its affiliates may, at any time, hold a trading position (long or short) in the securities and financial instruments discussed in this report.

BofA Securities, through business units other than BofA Global Research, may have issued and may in the future issue trading ideas or recommendations that are inconsistent with, and reach different conclusions from, the information presented herein. Such ideas or recommendations may reflect different time frames, assumptions, views and analytical methods of the persons who prepared them, and BofA Securities is under no obligation to ensure that such other trading ideas or recommendations are brought to the attention of any recipient of this information.

In the event that the recipient received this information pursuant to a contract between the recipient and BofAS for the provision of research services for a separate fee, and in connection therewith BofAS may be deemed to be acting as an investment adviser, such status relates, if at all, solely to the person with whom BofAS has contracted directly and does not extend beyond the delivery of this report (unless otherwise agreed specifically in writing by BofAS). If such recipient uses the services of BofAS in connection with the sale or purchase of a security referred to herein, BofAS may act as principal for its own account or as agent for another person. BofAS is and continues to act solely as a broker-dealer in connection with the execution of any transactions, including transactions in any securities referred to herein.

Copyright and General Information:

Copyright 2020 Bank of America Corporation. All rights reserved. iQprofileSM, iQmethodSM are service marks of Bank of America Corporation. iQdatabase[®] is a registered service mark of Bank of America Corporation. This information is prepared for the use of BofA Securities clients and may not be redistributed, retransmitted or disclosed, in whole or in part, or in any form or manner, without the express written consent of BofA Securities. BofA Global Research information is distributed simultaneously to internal and client websites and other portals by BofA Securities and is not publicly-available material. Any unauthorized use or disclosure is prohibited. Receipt and review of this information constitutes your agreement not to redistribute, retransmit, or disclose to others the contents, opinions, conclusion, or information contained herein (including any investment recommendations, estimates or price targets) without first obtaining express permission from an authorized officer of BofA Securities.

Materials prepared by BofA Global Research personnel are based on public information. Facts and views presented in this material have not been reviewed by, and may not reflect information known to, professionals in other business areas of BofA Securities, including investment banking personnel. BofA Securities has established information barriers between BofA Global Research and certain business groups. As a result, BofA Securities does not disclose certain client relationships with, or compensation received from, such issuers. To the extent this material discusses any legal proceeding or issues, it has not been prepared as nor is it intended to express any legal conclusion, opinion or advice. Investors should consult their own legal advisers as to issues of law relating to the subject matter of this material. BofA Global Research personnel's knowledge of legal proceedings in which any BofA Securities entity and/or its directors, officers and employees may be plaintiffs, defendants, co-defendants or co-plaintiffs with or involving issuers mentioned in this material is based on public information. Facts and views presented in this material that relate to any such proceedings have not been reviewed by, discussed with, and may not reflect information known to, professionals in other business areas of BofA Securities in connection with the legal proceedings or matters relevant to such proceedings.

This information has been prepared independently of any issuer of securities mentioned herein and not in connection with any proposed offering of securities or as agent of any issuer of any securities. None of BofAS or any of its affiliates or their research analysts has any authority whatsoever to make any representation or warranty on behalf of the issuer(s). BofA Global Research policy prohibits research personnel from disclosing a recommendation, investment rating, or investment thesis for review by an issuer prior to the publication of a research report containing such rating, recommendation or investment thesis.



Any information relating to the tax status of financial instruments discussed herein is not intended to provide tax advice or to be used by anyone to provide tax advice. Investors are urged to seek tax advice based on their particular circumstances from an independent tax professional.

The information herein (other than disclosure information relating to BofA Securities and its affiliates) was obtained from various sources and we do not guarantee its accuracy. This information may contain links to third-party websites. BofA Securities is not responsible for the content of any third-party website or any linked content contained in a third-party website. Content contained on such third-party websites is not part of this information and is not incorporated by reference. The inclusion of a link does not imply any endorsement by or any affiliation with BofA Securities. Access to any third-party website is at your own risk, and you should always review the terms and privacy policies at third-party websites before submitting any personal information to them. BofA Securities is not responsible for such terms and privacy policies and expressly disclaims any liability for them.

All opinions, projections and estimates constitute the judgment of the author as of the date of publication and are subject to change without notice. Prices also are subject to change without notice. BofA Securities is under no obligation to update this information and BofA Securities ability to publish information on the subject issuer(s) in the future is subject to applicable quiet periods. You should therefore assume that BofA Securities will not update any fact, circumstance or opinion contained herein.

Certain outstanding reports or investment opinions relating to securities, financial instruments and/or issuers may no longer be current. Always refer to the most recent research report relating to an issuer prior to making an investment decision.

In some cases, an issuer may be classified as Restricted or may be Under Review or Extended Review. In each case, investors should consider any investment opinion relating to such issuer (or its security and/or financial instruments) to be suspended or withdrawn and should not rely on the analyses and investment opinion(s) pertaining to such issuer (or its securities and/or financial instruments) nor should the analyses or opinion(s) be considered a solicitation of any kind. Sales persons and financial advisors affiliated with BofAS or any of its affiliates may not solicit purchases of securities or financial instruments that are Restricted or Under Review and may only solicit securities under Extended Review in accordance with firm policies.

Neither BofA Securities nor any officer or employee of BofA Securities accepts any liability whatsoever for any direct, indirect or consequential damages or losses arising from any use of this information.